Methods for predicting time-to-delivery in pregnant women
The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.
1. A method of predicting time to delivery (TTD), the method comprising:
(a) contacting a vaginal fluid sample obtained from a pregnant woman having intact fetal membranes, with at least two PAMG-1-specific monoclonal antibodies, wherein one or more of the at least two PAMG-1-specific monoclonal antibodies is an antibody selected from the group consisting of M271, produced by hybridoma N271, deposited with the Russian National Collection of Industrial Microorganisms (VKPM) Depository and assigned accession number VKPM-93; M52, produced by hybridoma N52, deposited with the VKPM and assigned accession number VKPM-92; and M42, produced by hybridoma N42, deposited with the VKPM and assigned accession number VKPM-94, wherein at least one of the antibodies binds to PAMG-1 when present in the sample to form a PAMG-1/monoclonal antibody complex;
(b) detecting the presence of the PAMG-1/monoclonal antibody complex in the sample only when the concentration of PAMG-1 in the sample exceeds a predefined detection threshold of 4 ng/ml; and
(c) predicting that the pregnant woman will deliver within a predetermined time frame if PAMG-1 is detected; or
(d) predicting that the pregnant woman will not deliver within the predetermined time frame if PAMG-1 is not detected, wherein the predetermined time frame is within 7 days.
2. The method of claim 1 , comprising collecting the vaginal fluid sample over a time period of about 30 seconds.
3. The method of claim 1 , wherein the vaginal fluid sample is contacted with the at least two PAMG-1-specific monoclonal antibodies for 5 minutes.
4. The method of claim 1 , wherein the method has one or more of the following positive predictive values (PPVs):
(i) at least 39% for predicting TTD within 48 hours;
(ii) at least 64% for predicting TTD within 7 days; and
(iii) at least 77% for predicting TTD within 14 days.
5. The method of claim 1 , wherein the method has one or more of the following PPVs:
(i) about 45.5% for predicting TTD within 48 hours;
(ii) about 78% for predicting TTD within 7 days; and
(iii) about 87% for predicting TTD within 14 days.
6. The method of claim 1 , wherein the method has a negative predictive value (NPV) of 87% or greater.
7. The method of claim 1 , wherein the method has one or more of the following NPVs:
(i) 100% for predicting TTD within 48 hours;
(ii) 97.4% for predicting TTD within 7 days; and
(iii) 93.6% for predicting TTD within 14 days.
8. The method of claim 1 , wherein the at least two PAMG-1 specific monoclonal antibodies are used in a lateral flow device.
9. The method of claim 8 , wherein the lateral flow device comprises a pad region and a test region.
10. The method of claim 9 , wherein the pad region of the test device comprises one of the at least two PAMG-1 specific monoclonal antibodies and the test region comprises the other of the two, and wherein the PAMG-1 specific monoclonal antibody in the pad region is mobilizable and the PAMG-1 specific monoclonal antibody in the test region is immobilized.
11. The method of claim 10 , wherein the test region of the test device further comprises a control region.
12. The method of claim 10 , where the mobilizable antibody in the pad region is M271, and the immobilized antibody in the test region is M52.